TLDR
- Novartis agreed to acquire experimental breast cancer drug SNV4818 from Synnovation Therapeutics for up to $3 billion
- The deal includes $2 billion upfront and up to $1 billion in milestone payments
- SNV4818 is a selective PI3Kα inhibitor targeting HR+/HER2- breast cancer
- The drug targets only the mutated form of PI3Kα, aiming to reduce side effects seen with existing therapies
- Novartis stock fell 0.94% on the news; deal expected to close in H1 2026
Novartis (NOVN) has agreed to acquire SNV4818, an experimental breast cancer drug, from U.S. biotech firm Synnovation Therapeutics in a deal worth up to $3 billion.
The Swiss drugmaker will pay $2 billion upfront. The remaining $1 billion is tied to future development milestones.
SNV4818 belongs to a class of drugs known as selective PI3Kα inhibitors. It targets a form of breast cancer classified as HR positive/HER2 negative, and could potentially be used against other solid tumors.
The drug is currently in early-stage clinical trials. Lab studies have shown it to be active against tumors, according to Novartis.
What sets SNV4818 apart is its precision. It targets only the mutated form of the PI3Kα enzyme — the version that malfunctions in cancer cells — while leaving the healthy version alone.
That selectivity matters. Existing PI3Kα-inhibiting therapies are known to carry side effects, and Synnovation’s drug is designed to improve on that profile.
A Gap in Breast Cancer Treatment
Shreeram Aradhye, Novartis’s chief medical officer, said the company sees a real unmet need here. “While mutated PI3Kα is a well-established driver in HR+/HER2- breast cancer, there remains a challenge in achieving effective pathway inhibition with a tolerable therapeutic profile,” he said.
SNV4818 is positioned as a potential answer to that challenge.
The acquisition fits into Novartis’s broader push in oncology. The company already has a radioligand therapy candidate in testing, and SNV4818 adds another targeted approach to that growing lineup.
Pipeline and Deal Timeline
Novartis said it expects the deal to close in the first half of 2026.
NOVN stock was down 0.94% on Friday following the announcement.
The deal adds a pre-commercial asset to Novartis’s pipeline at a time when the company is actively building out its cancer drug portfolio. SNV4818 remains in early-stage development, meaning it has several trial phases ahead before any potential approval.
Milestone payments of up to $1 billion will only be triggered if the drug clears specific development hurdles.
The total $3 billion price tag reflects both the upfront commitment and the potential value Novartis sees in the drug if it continues to progress through trials.
Synnovation Therapeutics is a U.S.-based biotech. This deal marks an exit of its lead asset to one of the world’s largest pharmaceutical companies.
NOVN stock was trading down 0.94% at the time of reporting.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
